Cardiovascular Safety Pharmacology of Sibutramine.
10.4062/biomolther.2015.033
- Author:
Jaesuk YUN
1
;
Eunyong CHUNG
;
Ki Hwan CHOI
;
Dae Hyun CHO
;
Yun Jeong SONG
;
Kyoung Moon HAN
;
Hey Jin CHA
;
Ji Soon SHIN
;
Won Keun SEONG
;
Young Hoon KIM
;
Hyung Soo KIM
Author Information
1. National Institute of Drug and Safety Evaluation, Ministry of Food and Drug Safety, Osong 363-700, Republic of Korea. kimhs58@korea.kr
- Publication Type:Original Article
- Keywords:
Anorectic;
Sibutramine;
QT prolongation;
Beagle dogs
- MeSH:
Action Potentials;
Animals;
Blood Pressure;
Cardiovascular System;
Counterfeit Drugs;
Dogs;
Heart Rate;
HEK293 Cells;
Inhibitory Concentration 50;
Pharmaceutical Preparations;
Pharmacology*;
Purkinje Fibers;
Rabbits;
Telemetry
- From:Biomolecules & Therapeutics
2015;23(4):386-389
- CountryRepublic of Korea
- Language:English
-
Abstract:
Sibutramine is an anorectic that has been banned since 2010 due to cardiovascular safety issues. However, counterfeit drugs or slimming products that include sibutramine are still available in the market. It has been reported that illegal sibutramine-contained pharmaceutical products induce cardiovascular crisis. However, the mechanism underlying sibutramine-induced cardiovascular adverse effect has not been fully evaluated yet. In this study, we performed cardiovascular safety pharmacology studies of sibutramine systemically using by hERG channel inhibition, action potential duration, and telemetry assays. Sibutramine inhibited hERG channel current of HEK293 cells with an IC50 of 3.92 muM in patch clamp assay and increased the heart rate and blood pressure (76 Deltabpm in heart rate and 51 DeltammHg in blood pressure) in beagle dogs at a dose of 30 mg/kg (per oral), while it shortened action potential duration (at 10 muM and 30 muM, resulted in 15% and 29% decreases in APD50, and 9% and 17% decreases in APD90, respectively) in the Purkinje fibers of rabbits and had no effects on the QTc interval in beagle dogs. These results suggest that sibutramine has a considerable adverse effect on the cardiovascular system and may contribute to accurate drug safety regulation.
